{"nctId":"NCT00782184","briefTitle":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","startDateStruct":{"date":"2008-11"},"conditions":["Hypercholesterolemia"],"count":250,"armGroups":[{"label":"ezetimibe/simvastatin 10/40","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe/simvastatin 10/40","Drug: atorvastatin 20 mg"]},{"label":"atorvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: atorvastatin 40 mg","Drug: atorvastatin 20 mg"]}],"interventions":[{"name":"ezetimibe/simvastatin 10/40","otherNames":["Vytorin"]},{"name":"atorvastatin 40 mg","otherNames":["Lipitor"]},{"name":"atorvastatin 20 mg","otherNames":["Lipitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who are either statin naive or on approved lipid lowering therapy for 6 weeks prior to study initiation\n* Participant meets Adult Treatment Panel (ATP) III High Risk criteria\n\nExclusion Criteria:\n\n* Females who are pregnant or breastfeeding\n* Participant consumes more than 14 alcoholic beverages per week\n* Participant has been treated with an investigational drug within the last 30 days\n* Participant has congestive heart failure (New York Heart Association \\[NYHA\\] Type III or IV)\n* Participant has had gastric bypass\n* Participant is newly diagnosed with type 1 or 2 diabetes\n* Participant is Human Immunodeficiency Virus (HIV) positive\n* Participant has a history of drug or alcohol abuse within the last 5 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants Reaching LDL-C Target Goals of <70 mg/dL","description":"Target LDL-C level of \\< 70 mg/dL (1.81 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Low Density Lipoprotein (LDL)-C","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.81","spread":"27.09"},{"groupId":"OG001","value":"-11.81","spread":"22.85"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reaching LDL-C Target Goal <77 mg/dL","description":"Target LDL-C level of \\< 77 mg/dL (2.00 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reaching LDL-C Target Goal <100 mg/dL","description":"Target LDL-C level of \\< 100 mg/dL (2.59 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.97","spread":null},{"groupId":"OG001","value":"-7.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.41","spread":null},{"groupId":"OG001","value":"-7.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.37","spread":null},{"groupId":"OG001","value":"2.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL Cholesterol","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.50","spread":null},{"groupId":"OG001","value":"-10.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.77","spread":null},{"groupId":"OG001","value":"-12.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.63","spread":null},{"groupId":"OG001","value":"-8.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.41","spread":null},{"groupId":"OG001","value":"-11.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.23","spread":null},{"groupId":"OG001","value":"-9.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":null},{"groupId":"OG001","value":"-2.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B/A-1 Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.59","spread":null},{"groupId":"OG001","value":"-5.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.18","spread":null},{"groupId":"OG001","value":"-8.86","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":119},"commonTop":["Constipation"]}}}